GlaxoSmithKline Market Cap 2006-2019 | GSK

GlaxoSmithKline market cap history and chart from 2006 to 2019. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. GlaxoSmithKline market cap as of January 24, 2020 is $117.8B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $117.802B $41.140B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $390.359B 17.09
Roche Holding AG (RHHBY) Switzerland $282.158B 0.00
Pfizer (PFE) United States $220.369B 13.10
Merck (MRK) United States $218.904B 16.96
Novartis AG (NVS) Switzerland $215.131B 18.16
Novo Nordisk (NVO) Denmark $144.638B 24.93
Eli Lilly (LLY) United States $133.525B 24.66
AstraZeneca (AZN) United Kingdom $129.299B 23.35
AbbVie (ABBV) United States $123.541B 9.68
Sanofi (SNY) France $122.027B 14.99
Bristol-Myers Squibb (BMY) United States $104.535B 14.61
Bayer (BAYRY) Germany $77.588B 11.49
H Lundbeck (HLUYY) Denmark $8.147B 14.16